Zusammenfassung
In diesem Übersichtsbeitrag werden neue Entwicklungen der photodynamischen Therapie (PDT) der letzten Jahre vorgestellt. Seit 2009 wurden zur Behandlung aktinischer Keratosen mit einem Aminolävulinsäure-haltigen Pflaster und einer Aminolävulinsäure-haltigen Nanoemulsion 2 neue Photosensibilisatoren zugelassen. Hinsichtlich penetrationsverbessernder Maßnahmen konnte gezeigt werden, dass durch Vorbehandlung mit einem ablativen fraktionierten Laser die Penetration des Photosensibilisators verbessert und eine intensivierte PDT akral und in feldkanzerisierter Haut ermöglicht wird. Die hautverjüngenden Effekte der PDT wurden in zahlreichen Studien nachgewiesen und die zugrunde liegenden Mechanismen aufgeklärt. Klinische Studien der letzten Jahre belegen die Wirksamkeit der PDT in der Behandlung und Prophylaxe von aktinischen Keratosen bei organtransplantierten Patienten, die ein stark erhöhtes Hautkrebsrisiko haben. Darüber hinaus wird auch die aktuelle Studienlage zur PDT mit Tageslicht (sog. Daylight-PDT) zusammengefasst.
Abstract
We review new developments in recent years in photodynamic therapy. Since 2009 two new photosensitizers, a self-adhesive 5-aminolevulinic acid (ALA) patch and a nanoemulsion formulation of 5-aminolevulinic acid have been approved for the treatment of actinic keratoses. Pretreatment with ablative fractional lasers enhances penetration of the photosensitizer and enables intensified PDT in acral lesions and in field-cancerized skin. Several clinical trials have demonstrated the skin-rejuvenating effects of photodynamic therapy, while the underlying mechanisms of action have been clarified. The efficacy of photodynamic therapy has been shown in the treatment and prophylaxis of actinic keratoses in organ transplant recipients at high risk for developing skin cancer. We also summarize the results of available studies on daylight-mediated photodynamic therapy.
Literatur
Babilas P, Knobler R, Hummel S et al (2007) Variable pulsed light is less painful than light-emitting diodes for topical photodynamic therapy of actinic keratosis: a prospective randomized controlled trial. Br J Dermatol 157:111–117
Bagazgoitia L, Cuevas Santos J, Juarranz A et al (2011) Photodynamic therapy reduces the histological features of actinic damage and the expression of early oncogenic markers. Br J Dermatol 165:144–151
Basset-Seguin N, Baumann Conzett K, Gerritsen MJ et al (2013) Photodynamic therapy for actinic keratosis in organ transplant patients. J Eur Acad Dermatol Venereol 27:57–66
Bencini PL, Galimberti MG, Pellacani G et al (2012) Application of photodynamic therapy combined with pre-illumination microneedling in the treatment of actinic keratosis in organ transplant recipients. Br J Dermatol 167:1193–1194
Berg D, Otley CC (2002) Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management. J Am Acad Dermatol 47:1–17 (quiz 18–20)
Braathen LR, Morton CA, Basset-Seguin N et al (2012) Photodynamic therapy for skin field cancerization: an international consensus. International Society for Photodynamic Therapy in Dermatology. J Eur Acad Dermatol Venereol 26(9):1063–1066
De Graaf YG, Kennedy C, Wolterbeek R et al (2006) Photodynamic therapy does not prevent cutaneous squamous-cell carcinoma in organ-transplant recipients: results of a randomized-controlled trial. J Invest Dermatol 126:569–574
Dirschka T, Radny P, Dominicus R et al (2012) Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placebo. Br J Dermatol 166:137–146
Dover JS, Bhatia AC, Stewart B et al (2005) Topical 5-aminolevulinic acid combined with intense pulsed light in the treatment of photoaging. Arch Dermatol 141:1247–1252
Dragieva G, Hafner J, Dummer R et al (2004) Topical photodynamic therapy in the treatment of actinic keratoses and Bowen’s disease in transplant recipients. Transplantation 77:115–121
Dragieva G, Prinz BM, Hafner J et al (2004) A randomized controlled clinical trial of topical photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratoses in transplant recipients. Br J Dermatol 151:196–200
Galitzer BI (2011) Effect of retinoid pretreatment on outcomes of patients treated by photodynamic therapy for actinic keratosis of the hand and forearm. J Drugs Dermatol 10:1124–1132
Glogau RG (2000) The risk of progression to invasive disease. J Am Acad Dermatol 42:23–24
Guleng GE, Helsing P (2012) Photodynamic therapy for basal cell carcinomas in organ-transplant recipients. Clin Exp Dermatol 37:367–369
Haddad A, Santos ID, Gragnani A et al (2011) The effect of increasing fluence on the treatment of actinic keratosis and photodamage by photodynamic therapy with 5-aminolevulinic acid and intense pulsed light. Photomed Laser Surg 29:427–432
Haedersdal M, Katsnelson J, Sakamoto FH et al (2011) Enhanced uptake and photoactivation of topical methyl aminolevulinate after fractional CO2 laser pretreatment. Lasers Surg Med 43:804–813
Hauschild A, Stockfleth E, Popp G et al (2009) Optimization of photodynamic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: results of two randomized controlled phase III studies. Br J Dermatol 160:1066–1074
Issa MC, Pineiro-Maceira J, Vieira MT et al (2010) Photorejuvenation with topical methyl aminolevulinate and red light: a randomized, prospective, clinical, histopathologic, and morphometric study. Dermatol Surg 36:39–48
Karrer S, Kohl E, Feise K et al (2013) Photodynamic therapy for skin rejuvenation: review and summary of the literature – results of a consensus conference of an expert group for aesthetic photodynamic therapy. J Dtsch Dermatol Ges 11:137–148
Kearney C, Brew D (2012) Single-session combination treatment with intense pulsed light and nonablative fractional photothermolysis: a split-face study. Dermatol Surg 38:1002–1009
Kohl E, Landthaler M, Szeimies RM (2009) Skin aging. Hautarzt 60:917–933 (quiz 934)
Leiter U, Garbe C (2010) Skin cancer in organ transplant patients. Epidemiology and management. Hautarzt 61:207–213
Maisch T, Moor AC, Regensburger J et al (2011) Intense pulse light and 5-ALA PDT: phototoxic effects in vitro depend on the spectral overlap with protoporphyrine IX but do not match cut-off filter notations. Lasers Surg Med 43:176–182
Maisch T, Szeimies RM, Jori G et al (2004) Antibacterial photodynamic therapy in dermatology. Photochem Photobiol Sci 3:907–917
Morley S, Griffiths J, Philips G et al (2013) Phase IIa randomized, placebo-controlled study of antimicrobial photodynamic therapy in bacterially colonized, chronic leg ulcers and diabetic foot ulcers: a new approach to antimicrobial therapy. Br J Dermatol 168:617–624
Perrett CM, Mcgregor JM, Warwick J et al (2007) Treatment of post-transplant premalignant skin disease: a randomized intrapatient comparative study of 5-fluorouracil cream and topical photodynamic therapy. Br J Dermatol 156:320–328
Piaserico S, Belloni Fortina A, Rigotti P et al (2007) Topical photodynamic therapy of actinic keratosis in renal transplant recipients. Transplant Proc 39:1847–1850
Ruiz-Rodriguez R, Lopez L, Candelas D et al (2008) Photorejuvenation using topical 5-methyl aminolevulinate and red light. J Drugs Dermatol 7:633–637
Ruiz-Rodriguez R, Lopez L, Candelas D et al (2007) Enhanced efficacy of photodynamic therapy after fractional resurfacing: fractional photodynamic rejuvenation. J Drugs Dermatol 6:818–820
Serra-Guillen C, Nagore E, Hueso L et al (2012) A randomized pilot comparative study of topical methyl aminolevulinate photodynamic therapy versus imiquimod 5 % versus sequential application of both therapies in immunocompetent patients with actinic keratosis: clinical and histologic outcomes. J Am Acad Dermatol 66:e131–e137
Szeimies RM, Stockfleth E, Popp G et al (2010) Long-term follow-up of photodynamic therapy with a self-adhesive 5-aminolaevulinic acid patch: 12 months data. Br J Dermatol 162:410–414
Szeimies RM, Torezan L, Niwa A et al (2012) Clinical, histopathological and immunohistochemical assessment of human skin field cancerization before and after photodynamic therapy. Br J Dermatol 167:150–159
Ulrich C, Bichel J, Euvrard S et al (2007) Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5 % cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. Br J Dermatol 157(Suppl 2):25–31
Wiegell SR, Fabricius S, Gniadecka M et al (2012) Daylight-mediated photodynamic therapy of moderate to thick actinic keratoses of the face and scalp: a randomized multicentre study. Br J Dermatol 166:1327–1332
Wiegell SR, Fabricius S, Stender IM et al (2011) A randomized, multicentre study of directed daylight exposure times of 1(1/2) vs. 2(1/2) h in daylight-mediated photodynamic therapy with methyl aminolaevulinate in patients with multiple thin actinic keratoses of the face and scalp. Br J Dermatol 164:1083–1090
Wiegell SR, Haedersdal M, Eriksen P et al (2009) Photodynamic therapy of actinic keratoses with 8 % and 16 % methyl aminolaevulinate and home-based daylight exposure: a double-blinded randomized clinical trial. Br J Dermatol 160:1308–1314
Wiegell SR, Haedersdal M, Philipsen PA et al (2008) Continuous activation of PpIX by daylight is as effective as and less painful than conventional photodynamic therapy for actinic keratoses; a randomized, controlled, single-blinded study. Br J Dermatol 158:740–746
Wiegell SR, Skodt V, Wulf HC (2013) Daylight-mediated photodynamic therapy of basal cell carcinomas – an explorative study. J Eur Acad Dermatol Venereol
Wiegell SR, Wulf HC, Szeimies RM et al (2012) Daylight photodynamic therapy for actinic keratosis: an international consensus: International Society for Photodynamic Therapy in Dermatology. J Eur Acad Dermatol Venereol 26:673–679
Willey A, Mehta S, Lee PK (2010) Reduction in the incidence of squamous cell carcinoma in solid organ transplant recipients treated with cyclic photodynamic therapy. Dermatol Surg 36:652–658
Wulf HC, Pavel S, Stender I et al (2006) Topical photodynamic therapy for prevention of new skin lesions in renal transplant recipients. Acta Derm Venereol 86:25–28
Zane C, Capezzera R, Sala R et al (2007) Clinical and echographic analysis of photodynamic therapy using methylaminolevulinate as sensitizer in the treatment of photodamaged facial skin. Lasers Surg Med 39:203–209
Wennberg AM, Stenquist B, Stockfleth E et al (2008) Photodynamic therapy with methyl aminolevulinate for prevention of new skin lesions in transplant recipients: a randomized study. Transplantation 86:423–429
Interessenkonflikt
Die korrespondierende Autorin weist für sich und ihren Koautor auf folgende Beziehungen hin: Fr. Prof. Karrer hält für Galderma Vorträge gegen Honorar und hat an Zulassungsstudien als Prüfärztin teilgenommen.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kohl, E., Karrer, S. Neue Entwicklungen in der photodynamischen Therapie. Hautarzt 64, 363–369 (2013). https://doi.org/10.1007/s00105-012-2513-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00105-012-2513-x